Jerlyn McCleod, MD
Child & Adolescent Psychiatry · Dothan, ALNPI 1972659407
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 477 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations. Among child & adolescent psychiatry clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 477 payments — averaging $19.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corium, LLC$1K
- Johnson & Johnson$1K
- AbbVie$876
- Supernus Pharmaceuticals, Inc.$771
- Vanda Pharmaceuticals Inc.$707
- Otsuka America Pharmaceutical, Inc.$681
- plus $4K from 21 others
What the payments were for
- Food & beverage$9,371100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corium, LLC | 68 | $1,385 |
| Johnson & Johnson | 59 | $1,359 |
| AbbVie(2 entities) | 66 | $876 |
| Supernus Pharmaceuticals, Inc. | 14 | $771 |
| Vanda Pharmaceuticals Inc. | 27 | $707 |
| Otsuka America Pharmaceutical, Inc. | 42 | $681 |
| Almatica Pharma LLC | 30 | $578 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 26 | $494 |
| Tris Pharma Inc | 25 | $413 |
| Ironshore Pharmaceuticals Inc. | 25 | $401 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $293 |
| Alkermes, Inc. | 12 | $230 |
| Axsome Therapeutics, Inc. | 10 | $187 |
| Neurocrine Biosciences, Inc. | 6 | $162 |
| Neos Therapeutics, LP | 9 | $143 |
| Eisai Inc. | 8 | $129 |
| Teva Pharmaceuticals USA, Inc. | 6 | $109 |
| Sunovion Pharmaceuticals Inc. | 8 | $104 |
| Shire North American Group Inc | 4 | $69 |
| E.r. Squibb & Sons, L.L.C. | 4 | $66 |
| Collegium Pharmaceutical, Inc. | 3 | $50 |
| Merck | 3 | $40 |
| Acadia Pharmaceuticals Inc | 2 | $36 |
| Idorsia Pharmaceuticals US Inc | 2 | $35 |
| Lundbeck LLC | 1 | $20 |
| Sage Therapeutics, LLC | 1 | $19 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,371 in reported general payments places this provider in the 90th percentile of 40 child & adolescent psychiatry providers in Alabama.
See all child & adolescent psychiatry providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 56 | $115,972 |
| VraylarCariprazine Hcl | 43 | $72,072 |
| Abilify MaintenaAripiprazole | 13 | $41,681 |
| VyvanseLisdexamfetamine Dimesylate | 23 | $9,338 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 87 | $5,164 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 137 | $5,101 |
| AzstarysSerdexmethylphen/Dexmethylphen | 12 | $5,055 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 35 | $3,238 |
| Paliperidone ErPaliperidone | 30 | $2,823 |
| Lisdexamfetamine Dimesylate | 13 | $2,496 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 24 | $2,257 |
| Oxcarbazepine | 25 | $1,834 |
| Atomoxetine Hcl | 20 | $1,779 |
| Divalproex Sodium | 31 | $1,647 |
| Fluvoxamine Maleate | 27 | $1,476 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $1,359 | $115,97256 claims |
| AbbVieVraylar | $876 | $72,07243 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $681 | $41,68113 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $293 | $9,33823 claims |
| Corium, LLCAzstarys | $1,385 | $5,05512 claims |
| Almatica Pharma LLCSertraline Hcl | $578 | $44347 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 40 child & adolescent psychiatry providers in Alabama.
Other child & adolescent psychiatry in Dothan
- Nelson HandalDothan$80K
- Artie NelsonBirmingham$32K
- Karen CallahanBirmingham$5K
- Curtis AdamsHuntsville$5K
- Casey LowreyBirmingham$4K
- Aparna VuppalaHuntsville$3K
- Richard SinclairMobile$2K
- John Broderick-CantwellDaphne$2K
- Christiana WilkinsOpelika$1K
- Elizabeth FergusonBirmingham$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.